ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

trastuzumab deruxtecan

Also written as “Trastuzumab deruxtecan”, “Trastuzumab Deruxtecan” and “DS-8201a”.

Its studies are mostly in Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms · Neoplasm Metastasis · Endometrial Neoplasms, led by 4 companies.

Drug pageTrastuzumab deruxtecan: every studyAll 120 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 13, 201849 company-led studies, 31 open or runningNext primary completion: Feb 10, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Daiichi Sankyoits history only2611 open or runningphase 3since Apr 13, 2018Sep 21, 2015Oct 1, 2027phase 3 · NCT05950945
AstraZeneca2120 open or runningphase 4since May 21, 2024Sep 22, 2017Feb 10, 2027phase 2 · NCT06271837
Pfizerits history only10 open or runningphase 2since Aug 31, 2020Aug 31, 2020none ahead
Strata Oncologyits history only10 open or runningphase 2since Oct 1, 2021Oct 1, 2021none ahead

Also a collaborator on its studies: Merck, Parexel, Bristol-Myers Squibb and Gilead Sciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 8 earlier studies, Sep 22, 2017 to Oct 26, 2020.

  1. Dec 9, 2016Named trastuzumab deruxtecanINNProposed as its International Nonproprietary Name in WHO's List 116
  2. Dec 8, 2020Phase 1 study in Carcinoma, Non-Small-Cell LungNCT04686305 · 304 planned · United States, Australia, Belgium and more
  3. Jan 20, 2021Phase 3 study in Breast NeoplasmsNCT04739761 · 506 enrolled · United States, Australia, Belgium and more
  4. Feb 19, 2021Phase 3 study in Breast NeoplasmsNCT04784715 · 1,157 enrolled · United States, Argentina, Belgium and more
  5. Jul 14, 2021Phase 2 study in AdenocarcinomaNCT04989816 · 95 enrolled · China
  6. Sep 9, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05048797 · 454 enrolled · United States, Austria, Belgium and more
  7. Oct 22, 2021Phase 3 study in Breast NeoplasmsNCT05113251 · 927 enrolled · United States, Brazil, Bulgaria and more
  8. Feb 11, 2022Phase 2 study in HER2-mutant Non-Small Cell Lung CancerNCT05246514 · 72 enrolled · China
  9. Jan 19, 2024Phase 2 study in Breast NeoplasmsNCT06271837 · 127 enrolled · China
  10. May 21, 2024Phase 3 study in Biliary Tract NeoplasmsNCT06467357 · 620 planned · United States, Australia, Austria and more
  11. May 21, 2024Phase 4 study in Breast NeoplasmsNCT06429761 · 100 enrolled · India
  12. Dec 12, 2024Phase 3 study in HER2-positive Gastric CancerNCT06764875 · 840 planned · United States, Argentina, Australia and more
  13. Mar 11, 2025Phase 3 study in Endometrial NeoplasmsNCT06989112 · 600 planned · United States, Australia, Austria and more
  14. Jun 24, 2025Phase 2 study in Stomach NeoplasmsNCT07069712 · 100 planned · United States, Canada, China and more
  15. Oct 22, 2026Primary completion moved from 2026-11-11 to 2027-05-03Date moved laterphase 3 · +6 months · NCT04784715

Ahead

  1. Feb 10, 2027Primary completion: phase 2 study in Breast NeoplasmsNCT06271837
  2. Mar 23, 2027Primary completion: phase 2 study in Pancreatic NeoplasmsNCT04482309
  3. May 3, 2027Primary completion: phase 3 study in Breast NeoplasmsNCT04784715
  4. May 4, 2027Primary completion: phase 2 study in Stomach NeoplasmsNCT04379596

TargetBeta

ERBB2 →read by rule
“An antibody-drug conjugate (ADC) composed of trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (ERBB2; EGFR2; HER2) ”NCIt, by rule
“Receptor protein-tyrosine kinase erbB-2 binding agent”ChEMBL 37, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312
anbenitamabCSPC Pharmaceutical Groupphase 312

Studies

All 21 AstraZeneca leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07069712Stomach Neoplasms · United States, Canada, China and more2RecruitingNov 9, 2027100
NCT06989112Endometrial Neoplasms · United States, Australia, Austria and more3RecruitingJan 19, 2029600
NCT06764875HER2-positive Gastric Cancer · United States, Argentina, Australia and more3RecruitingApr 27, 2029840
NCT06467357Biliary Tract Neoplasms · United States, Australia, Austria and more3RecruitingJun 12, 2028620
NCT06429761Breast Neoplasms · India4Active, not recruitingOct 31, 2026100
NCT06271837Breast Neoplasms · China2Active, not recruitingFeb 10, 2027127
NCT05246514HER2-mutant Non-Small Cell Lung Cancer · China2Active, not recruitingNov 4, 202472
NCT05113251Breast Neoplasms · United States, Brazil, Bulgaria and more3Active, not recruitingMar 12, 2025927
NCT05048797Carcinoma, Non-Small-Cell Lung · United States, Austria, Belgium and more3Active, not recruitingJun 9, 2026454
NCT04989816Adenocarcinoma · China2CompletedJun 16, 202395
NCT04784715Breast Neoplasms · United States, Argentina, Belgium and more3Active, not recruitingMay 3, 20271,157
NCT04739761Breast Neoplasms · United States, Australia, Belgium and more3Active, not recruitingFeb 8, 2024506
NCT04686305Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more1RecruitingJun 30, 2027304
NCT04639219Neoplasm Metastasis · United States, Belgium, Canada and more2Active, not recruitingJan 25, 2023102
NCT04556773Breast Neoplasms · United States, Australia, Belgium and more1Active, not recruitingAug 16, 2023138
NCT04538742Breast Neoplasms · United States, Australia, Brazil and more2Active, not recruitingJan 31, 2025245
NCT04494425Breast Neoplasms · United States, Argentina, Australia and more3Active, not recruitingMar 18, 2024866
NCT04482309Pancreatic Neoplasms · United States, Australia, Belgium and more2Active, not recruitingMar 23, 2027477
NCT04379596Stomach Neoplasms · United States, Brazil, Canada and more2Active, not recruitingMay 4, 2027452
NCT03742102Triple Negative Breast Neoplasms · United States, Canada, Poland and more2Active, not recruitingNov 29, 2024243
NCT03334617Carcinoma, Non-Small-Cell Lung · United States, Austria, Canada and more2Active, not recruitingSep 13, 2024528

How it is read

Names in the registry

  • “Trastuzumab deruxtecan”, 22 entries
  • “Trastuzumab Deruxtecan”, 10 entries
  • “DS-8201a”, 7 entries
  • “Trastuzumab deruxtecan (DS-8201a)”, 3 entries
  • “T-DXd”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.